New hope for hepatitis c relapse: triple therapy aims for cure
NCT ID NCT01466192
First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 108 adults with genotype 2 hepatitis C whose infection returned after previous treatment. The goal was to see if the combination could clear the virus completely 24 weeks after treatment ended. Participants did not have cirrhosis or other serious liver conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Toranomon Hospital
Minato-ku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.